Nausea drug success

Israel’s Redhill Biopharma announced success in Phase III trials of RHB-102 – a once-a-day pill for the prevention of nausea in cancer patients. Redhill now plans to apply to the US Food and Drug Administration for a pre-New Drug Application (NDA) hearing for marketing approval for RHB-102.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published.